Tradewinds LLC. Makes New $371,000 Investment in Exact Sciences Co. (NASDAQ:EXAS)

Tradewinds LLC. bought a new position in Exact Sciences Co. (NASDAQ:EXAS - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 6,607 shares of the medical research company's stock, valued at approximately $371,000.

A number of other institutional investors and hedge funds have also bought and sold shares of the business. Thompson Investment Management Inc. grew its stake in shares of Exact Sciences by 17.8% during the fourth quarter. Thompson Investment Management Inc. now owns 241,774 shares of the medical research company's stock valued at $13,585,000 after buying an additional 36,505 shares during the last quarter. Zacks Investment Management bought a new position in Exact Sciences during the 3rd quarter worth approximately $2,083,000. Harbor Capital Advisors Inc. grew its position in Exact Sciences by 35.3% during the 4th quarter. Harbor Capital Advisors Inc. now owns 95,827 shares of the medical research company's stock worth $5,385,000 after acquiring an additional 24,992 shares during the last quarter. Jones Financial Companies Lllp increased its stake in Exact Sciences by 32.2% in the 4th quarter. Jones Financial Companies Lllp now owns 9,508 shares of the medical research company's stock worth $534,000 after purchasing an additional 2,315 shares during the period. Finally, Pier Capital LLC bought a new stake in Exact Sciences in the third quarter valued at approximately $5,520,000. 88.82% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on EXAS. William Blair restated an "outperform" rating on shares of Exact Sciences in a report on Thursday, February 20th. Guggenheim set a $60.00 price target on shares of Exact Sciences and gave the stock a "buy" rating in a report on Friday, March 28th. Bank of America lowered their price objective on shares of Exact Sciences from $72.00 to $65.00 and set a "buy" rating for the company in a research note on Thursday, February 20th. Barclays cut their target price on Exact Sciences from $70.00 to $65.00 and set an "overweight" rating on the stock in a research note on Thursday, February 20th. Finally, Benchmark reaffirmed a "buy" rating and set a $65.00 price target on shares of Exact Sciences in a research report on Monday, January 13th. Two investment analysts have rated the stock with a hold rating and nineteen have assigned a buy rating to the company's stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $70.26.

Exact Sciences Stock Down 3.9 %

Shares of NASDAQ EXAS traded down $1.73 on Friday, reaching $42.55. 4,616,199 shares of the company's stock traded hands, compared to its average volume of 2,579,934. The company has a quick ratio of 1.93, a current ratio of 2.15 and a debt-to-equity ratio of 0.97. The business's 50 day simple moving average is $48.64 and its two-hundred day simple moving average is $56.98. Exact Sciences Co. has a 12 month low of $40.62 and a 12 month high of $74.44. The company has a market cap of $7.90 billion, a price-to-earnings ratio of -7.64 and a beta of 1.14.

Exact Sciences (NASDAQ:EXAS - Get Free Report) last announced its quarterly earnings data on Wednesday, February 19th. The medical research company reported ($0.06) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.29) by $0.23. Exact Sciences had a negative return on equity of 5.29% and a negative net margin of 37.29%. The business had revenue of $713.42 million during the quarter, compared to analysts' expectations of $701.45 million. As a group, equities research analysts forecast that Exact Sciences Co. will post -0.58 EPS for the current fiscal year.

Exact Sciences Company Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.